- BiondVax has released statistically significant results showing efficacy of its inhaled NanoAb as anti-COVID-19 therapy, as part of a preclinical proof-of-concept animal study
- The study was conducted in collaboration with the world-renowned institutes Fraunhofer Institute for Toxicology and Experimental Medicine (“ITEM”) and The University of Veterinary Medicine Hannover (“TiHo”)
- The technology is exclusively licensed from the prestigious Max Planck Institute for Multidisciplinary Sciences and the University Medical Center Gottingen
- CEO Amir Reichman is scheduled to present in person at the Biotech Showcase (San Francisco – January 9th during JPM Healthcare conference week) and the BIO CEO & Investor Conference (New York – February 6th)
BiondVax Pharmaceuticals (NASDAQ: BVXV), a biotechnology company focused on the development, manufacturing, and commercialization of innovative immunotherapeutic products used primarily for the treatment of infectious and autoimmune diseases, recently released key financials for the quarter ending September 30, 2022, and highlighted important business updates (https://ibn.fm/NlQaQ).
The company is developing a pipeline of innovative nanosized antibody (NanoAb) therapies to address diseases underserved by current treatments and with large, growing markets, including infectious and autoimmune diseases such as COVID-19, asthma, psoriasis, psoriatic arthritis and…
NOTE TO INVESTORS: The latest news and updates relating to BVXV are available in the company’s newsroom at https://ibn.fm/BVXV
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to millions of social media followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)
For more information, please visit https://www.biomedwire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
